Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
Northend, Michael Wilson, William Osborne, Wendy Fox, Christopher P Davies, Andrew J El-Sharkawi, Dima Phillips, Elizabeth H Sim, Hau Wui Sadullah, Shalal Shah, Nimish
Northend, Michael
Wilson, William
Osborne, Wendy
Fox, Christopher P
Davies, Andrew J
El-Sharkawi, Dima
Phillips, Elizabeth H
Sim, Hau Wui
Sadullah, Shalal
Shah, Nimish
Citations
Altmetric:
Affiliation
University College Hospital; Cancer Research United Kingdom; UCL Cancer Trials Centre; The Newcastle-upon-Tyne Hospitals NHS Foundation Trust; Nottingham University Hospitals NHS Trust; University of Southampton; Southampton General Hospital; The Royal Marsden Hospital; The Christie Hospital; University of Manchester; Northwick Park Hospital; James Paget University Hospital; Norfolk & Norwich University Hospital; St George's Hospital; University Hospitals Birmingham NHS Foundation Trust; University Hospital of Derby & Burton NHS Foundation Trust; University Hospitals of North Midlands NHS Trust; King's College Hospital NHS Foundation Trust; Manchester University NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; Beatson West of Scotland Cancer Centre; The Clatterbridge Cancer Centre; East Sussex Healthcare NHS Trust; Dorset County Hospital; Royal Cornwall Hospital; Liverpool University Hospital NHS Foundation Trust; Leeds Teaching Hospitals NHS Trust; Bart's Health NHS Trust; Northumbria Healthcare NHS Foundation Trust; Western General Hospital; Brighton & Sussex University Hospitals NHS Trust
Other Contributors
Publication date
2022-05-09
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
No abstract available
Citation
Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, Phillips EH, Sim HW, Sadullah S, Shah N, Peng YY, Qureshi I, Addada J, Mora RF, Phillips N, Kuhnl A, Davies E, Wrench D, McKay P, Karpha I, Cowley A, Karim R, Challenor S, Singh V, Burton C, Auer R, Williams C, Cunningham J, Broom A, Arasaretnam A, Roddie C, Menne T, Townsend W. Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953.
Type
Correspondence